Shanghai Orsin Medical Technology Co., Ltd.
Shanghai Orsin Medical Technology Co., Ltd.
products
Home /

products

Cell Free DNA 10ml Reduced Patient Risk Early Disease Detection Cancer

Product Details

Place of Origin: China

Brand Name: Orsin

Payment & Shipping Terms

Minimum Order Quantity: 100

Price: Negotiation

Payment Terms: L/C, D/A, D/P, T/T, Western Union

Get Best Price
Chat Now
Specifications
Highlight:

10ml Cell Free DNA

,

Glass Cell Free DNA 10ml

Color:
Purple
Application:
Early Disease Detection
Material:
Glass And Pet
Advantage:
Sterile And Safe Compatible With Equipment
Trait:
Cancer
Capacity:
10ml
Color:
Purple
Application:
Early Disease Detection
Material:
Glass And Pet
Advantage:
Sterile And Safe Compatible With Equipment
Trait:
Cancer
Capacity:
10ml
Description
Cell Free DNA 10ml Reduced Patient Risk Early Disease Detection Cancer
Cell Free DNA 10ml Reduced Patient Risk Early Disease Detection Cancer
Attribute Value
Color Purple
Application Early Disease Detection
Material Glass and pet
Advantage Sterile And Safe Compatible With Equipment
Trait Cancer
Capacity 10ml
Orsin Medical Technology - Cell-Free DNA (cfDNA) Extraction & Analysis Solutions
Product Description

Orsin Medical Technology delivers high-efficiency, ultra-sensitive cfDNA extraction and detection products, designed for liquid biopsy, non-invasive prenatal testing (NIPT), cancer early screening, and transplant monitoring.

Key Advantages
  • Ultra-Low Input Compatibility - Reliable extraction even from minimal samples (e.g., 1mL plasma)
  • High Recovery Rate & Minimal Fragmentation - Proprietary technology preserves short fragments (~150-200bp), ensuring optimal ctDNA/fetal DNA capture
  • Automation-Ready - Supports high-throughput processing for clinical and research applications
  • Multi-Platform Compatibility - Seamless integration with qPCR, ddPCR, NGS, and other downstream analyses
Applications
  • Cancer Monitoring - Dynamic tumor burden tracking & treatment response
  • NIPT - Safe, accurate fetal genetic screening
  • Transplant Rejection Surveillance - Donor-derived cfDNA (dd-cfDNA) detection
Purer cfDNA, Stronger Diagnostics — Orsin Medical Technology, Powering Precision Medicine
Technical Specifications & Competitive Advantages
Core Performance Parameters
Parameter Orsin Technology Industry Standard (Typical)
Input Volume 0.5-2 mL plasma (ultra-low input compatible) 3-10 mL plasma
Yield Efficiency >85% recovery (50-200bp fragments) 60-75% recovery
Fragment Retention Optimized for 50-300bp (critical for ctDNA) Bias toward >150bp
Process Time 30 min (semi-automated) / 96 samples in 2h 2-4 hours (manual)
Inhibitor Removal PCR/NGS-compatible (A260/A280: 1.8-2.0) Frequent heparin/hemoglobin interference
Key Differentiators vs Competitors
Feature Orsin Advantage Common Limitations Elsewhere
Short-DNA Capture Proprietary silica beads + size-selection Loss of <100bp ctDNA
Automation Fully compatible with KingFisher/Hamilton Manual column-based kits
Multiplexing Simultaneous extraction of cfDNA+exosomes* cfDNA-only isolation
Cost per Sample ~$15 (high-throughput) $20-50 (competitor kits)
Downstream Compatibility
  • NGS: <5% adapter dimers (vs 15-30% in standard kits)
  • ddPCR: CV <3% for low-abundance mutations (0.1% VAF)
  • Methylation Analysis: Preserves epigenetic signatures
Validation Data
  • LoD: 0.01% mutant allele frequency (MAF) in 5ng cfDNA
  • Reproducibility: 98% concordance in 500+ clinical samples
At Orsin Medical Technology, we combine cutting-edge innovation with clinical practicality to redefine liquid biopsy standards. Our cfDNA solutions are:

Validated - Rigorously tested in CAP/CLIA environments
Scalable - From research to high-volume clinical labs
Evolving - Continuous optimization for emerging biomarkers (e.g., fragmentomics, methylation patterns)

Partner with us to unlock the full potential of liquid biopsy. Contact our technical team for assay validation protocols & application-specific protocols.

Send your inquiry
Please send us your request and we will reply to you as soon as possible.
Send